XML 102 R82.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Quarterly Financial Information (unaudited) (Parenthetical) (Details) - Novartis [Member] - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2017 | Jun. 30, 2017 | Dec. 31, 2017
Error Corrections And Prior Period Adjustments Restatement [Line Items] |  |  |
License fee revenue recognized | $ 35.4 |  |
Collaborative Arrangement [Member] |  |  |
Error Corrections And Prior Period Adjustments Restatement [Line Items] |  |  |
Milestone received under the collaboration agreement |  | $ 10.0 | $ 10.0

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Refers to the payment percentage of milestone received under the collaboration agreement. + References No definition available. + Details
Name: | xoma_MilestoneReceivedUnderCollaborationAgreement
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |